Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Jan 12, 2017
    TEL-AVIV, Israel, Jan. 12, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory disea...
    PDF
    Jan 11, 2017
    RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection     Under FDA's Generating Antibiotic Incentives Now (GAIN) Act, QIDP designation allows for Fast-Track status and Priority Review, potentially leading to a shorter NDA review time by th...
    PDF
    Jan 10, 2017
    The first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic (PK) study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a food-effect study with RHB-105 in healthy volunteersThe confirmatory Phase III study with RHB-105 for H. pylori infection is planned to be initiated, subj...
    PDF
    Jan 9, 2017
    TEL-AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dis...
    PDF
    Jan 9, 2017
    Members of RedHill's Board of Directors, senior management and Advisory Board have exercised stock options to purchase an aggregate of 1,700,000 ordinary shares (equivalent to 170,000 American Depositary Shares (ADSs)) during the last weekFollowing issuance of the ordinary shares underlying these stock options, the total number of outstanding ordin...
    PDF
    Jan 6, 2017
    The abstract, to be presented at the upcoming 2017 Cholangiocarcinoma Foundation Annual Conference, describes positive findings from non-clinical studies and the Phase I clinical study with YELIVA® (ABC294640), suggesting that YELIVA® may be an effective drug for the treatment of cholangiocarcinoma A Phase I study with YELIVA® in pa...
    PDF
    Jan 5, 2017
    The new research collaboration follows previous non-clinical studies conducted with Denmark's Aarhus University and is designed to identify additional high affinity molecular targets of MESUPRON (upamostat)Further evaluation of MESUPRON, together with Aarhus University, may allow for selection of appropriate sub populations of patients toward demon...
    PDF
    Jan 4, 2017
    TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dis...
    PDF
    Jan 3, 2017
    TEL-AVIV, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dis...
    PDF
    Jan 3, 2017
    RedHill and Concordia entered into an exclusive co-promotion agreement, granting RedHill certain U.S. promotion rights for Donnatal®Donnatal®1, Tablets and Elixir (syrup), is a prescription oral drug used with other drugs for the treatment of irritable bowel syndrome (IBS) and acute enterocolitis (inflammation of the small bowel)Under the...
    PDF
    Page: FirstPrevious
    2
    ... NextLast

    Subscribe to press releases